All In Biotech

NDA 020918 · Novo Nordisk

Glucagen

Glucagon Hydrochloride · Intramuscular, Intravenous, Intramuscular, Intravenous, Subcutaneous

Priority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Jul 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jun 22, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,156

249 Phase 3, 174 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 22, 1998 Original approval · Type 3 - New Dosage Form · priority review ReviewLabelLetter
2 products under this application
  • GLUCAGEN · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAMUSCULAR, INTRAVENOUS · Discontinued
  • GLUCAGEN · GLUCAGON HYDROCHLORIDE EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Glucagon" as an intervention, any sponsor and status, largest first.

All 1,156 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Glucagen (Glucagon)

2024 spending

$3.5M

Beneficiaries

6,698

9,424 claims

Per beneficiary

$526

$315.61 per unit

View as table
YearSpending
2020$18,155,989
2021$8,610,124
2022$5,888,486
2023$4,903,701
2024$3,521,871

Part B: Glucagen* (Glucagon*) · HCPCS J1610

2024 spending

$4.8M

Beneficiaries

21,431

22,838 claims

Per beneficiary

$222

2024 ASP limit $190.41 per unit

View as table
YearSpending
2020$8,481,071
2021$8,005,095
2022$7,391,309
2023$5,792,255
2024$4,763,004

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,332 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.